U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H23ClN6O2.ClH
Molecular Weight 487.382
Optical Activity ( - )
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SUVOREXANT HYDROCHLORIDE

SMILES

Cl.C[C@@H]1CCN(CCN1C(=O)C2=C(C=CC(C)=C2)N3N=CC=N3)C4=NC5=C(O4)C=CC(Cl)=C5

InChI

InChIKey=BIIYCWIUJHUUAO-PKLMIRHRSA-N
InChI=1S/C23H23ClN6O2.ClH/c1-15-3-5-20(30-25-8-9-26-30)18(13-15)22(31)29-12-11-28(10-7-16(29)2)23-27-19-14-17(24)4-6-21(19)32-23;/h3-6,8-9,13-14,16H,7,10-12H2,1-2H3;1H/t16-;/m1./s1

HIDE SMILES / InChI

Molecular Formula C23H23ClN6O2
Molecular Weight 450.921
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204569s001lbl.pdf; http://www.ncbi.nlm.nih.gov/pubmed/?term=24102345

Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R. It has been approved for the treatment of insomnia. The mechanism by which suvorexant exerts its therapeutic effect in insomnia is presumed to be through antagonism of orexin receptors. The orexin neuropeptide signaling system is a central promoter of wakefulness. Blocking the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R is thought to suppress wake drive.

Originator

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: O43614
Gene ID: 3062.0
Gene Symbol: HCRTR2
Target Organism: Homo sapiens (Human)
0.55 nM [Ki]
Target ID: O43613
Gene ID: 3061.0
Gene Symbol: HCRTR1
Target Organism: Homo sapiens (Human)
0.35 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
BELSOMRA

Approved Use

Indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

Launch Date

2014
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.08 μM
40 mg 1 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.329 μM
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.425 μM
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1.488 μM
80 mg 1 times / day steady-state, oral
dose: 80 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2.085 μM
100 mg 1 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.356 μM
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.414 μM
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.572 μM
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.574 μM
20 mg 1 times / day steady-state, oral
dose: 20 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.802 μM
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.854 uM
20 mg single, oral
dose: 20 mg
route of administration: oral
experiment type: single
co-administered:
SUVOREXANT plasma
Homo sapiens
population: healthy
age:
sex:
food status: Fasted
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
10.64 μM × h
40 mg 1 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
11.48 μM × h
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
18.1 μM × h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
18.32 μM × h
80 mg 1 times / day steady-state, oral
dose: 80 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
27.62 μM × h
100 mg 1 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
3.43 μM × h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4.36 μM × h
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5.03 μM × h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
6.08 μM × h
20 mg 1 times / day steady-state, oral
dose: 20 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
8.53 μM × h
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
9.4 h
40 mg 1 times / day steady-state, oral
dose: 40 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
10 h
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
12.6 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
11.2 h
80 mg 1 times / day steady-state, oral
dose: 80 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
14.5 h
100 mg 1 times / day steady-state, oral
dose: 100 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
7.7 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
8.1 h
10 mg 1 times / day steady-state, oral
dose: 10 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
8.4 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
9.2 h
20 mg 1 times / day steady-state, oral
dose: 20 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
8.6 h
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUVOREXANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
12 h
SUVOREXANT plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
SUVOREXANT plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
100 mg 1 times / day steady, oral
Highest studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
healthy, 34.3 years(range: 19–45 years)
n = 6
Health Status: healthy
Age Group: 34.3 years(range: 19–45 years)
Sex: M+F
Population Size: 6
Sources:
Other AEs: Somnolence, Fatigue...
Other AEs:
Somnolence (67%)
Fatigue (83%)
Insomnia (17%)
Dizziness (33%)
Phlebitis (33%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Insomnia 17%
100 mg 1 times / day steady, oral
Highest studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
healthy, 34.3 years(range: 19–45 years)
n = 6
Health Status: healthy
Age Group: 34.3 years(range: 19–45 years)
Sex: M+F
Population Size: 6
Sources:
Dizziness 33%
100 mg 1 times / day steady, oral
Highest studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
healthy, 34.3 years(range: 19–45 years)
n = 6
Health Status: healthy
Age Group: 34.3 years(range: 19–45 years)
Sex: M+F
Population Size: 6
Sources:
Phlebitis 33%
100 mg 1 times / day steady, oral
Highest studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
healthy, 34.3 years(range: 19–45 years)
n = 6
Health Status: healthy
Age Group: 34.3 years(range: 19–45 years)
Sex: M+F
Population Size: 6
Sources:
Somnolence 67%
100 mg 1 times / day steady, oral
Highest studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
healthy, 34.3 years(range: 19–45 years)
n = 6
Health Status: healthy
Age Group: 34.3 years(range: 19–45 years)
Sex: M+F
Population Size: 6
Sources:
Fatigue 83%
100 mg 1 times / day steady, oral
Highest studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: steady
Dose: 100 mg, 1 times / day
Sources:
healthy, 34.3 years(range: 19–45 years)
n = 6
Health Status: healthy
Age Group: 34.3 years(range: 19–45 years)
Sex: M+F
Population Size: 6
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 5.3 uM]
no [IC50 >100 uM]
no
weak [IC50 11 uM]
weak [IC50 15 uM]
weak [IC50 15 uM]
weak [IC50 17 uM]
weak [IC50 35 uM]
weak [IC50 37 uM]
weak [IC50 39 uM]
weak [IC50 44 uM]
weak [IC50 47 uM]
weak [IC50 64 uM]
weak [IC50 74 uM]
weak
yes [IC50 1.3 uM]
yes [IC50 10 uM]
yes [IC50 4 uM]
yes [IC50 73 uM]
yes [Inhibition 15 uM]
yes [Inhibition 15 uM]
yes
yes
yes
Drug as victim
PubMed

PubMed

TitleDatePubMed
Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist.
2011 Mar
The hypocretins/orexins: integrators of multiple physiological functions.
2014 Jan
Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.
2014 May
Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.
2015 Apr
Patents

Sample Use Guides

The recommended dose for BELSOMRA (suvorexant) is 10 mg, taken no more than once per night and within 30 minutes of going to bed, with at least 7 hours remaining before the planned time of awakening. If the 10 mg dose is well-tolerated but not effective, the dose can be increased. The maximum recommended dose of BELSOMRA is 20 mg once daily
Route of Administration: Oral
Examination of Suvorexant in radioligand binding assays using tissue from transgenic rats expressing the human OX2R found nearly full receptor occupancy (>90%) at plasma exposures of 1.1 μM.
Substance Class Chemical
Created
by admin
on Sat Dec 16 18:37:41 GMT 2023
Edited
by admin
on Sat Dec 16 18:37:41 GMT 2023
Record UNII
5D3S2VQZ54
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SUVOREXANT HYDROCHLORIDE
Common Name English
METHANONE, ((7R)-4-(5-CHLORO-2-BENZOXAZOLYL)HEXAHYDRO-7-METHYL-1H-1,4-DIAZEPIN-1-YL)(5-METHYL-2-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)-, HYDROCHLORIDE (1:1)
Systematic Name English
Code System Code Type Description
FDA UNII
5D3S2VQZ54
Created by admin on Sat Dec 16 18:37:41 GMT 2023 , Edited by admin on Sat Dec 16 18:37:41 GMT 2023
PRIMARY
PUBCHEM
102004303
Created by admin on Sat Dec 16 18:37:41 GMT 2023 , Edited by admin on Sat Dec 16 18:37:41 GMT 2023
PRIMARY
CAS
1818333-03-7
Created by admin on Sat Dec 16 18:37:41 GMT 2023 , Edited by admin on Sat Dec 16 18:37:41 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY